1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer>

Anti-human CD38 multi-epitope reagent

Anti-CD38 monoclonal antibodies continue to demonstrate promising results as new treatments for patients with multiple myeloma. Therapeutic anti-CD38 targets this molecule, highly expressed on the surface of multiple myeloma cells, hampering its detection by flow cytometry.

Anti-human CD38 multi-epitope reagent


Cytognos has developed an anti-human CD38 multi-epitope reagent containing a mixture of antibodies that allows the identification by flow cytometry of CD38 molecule on plasma cells, even in patients under anti-CD38 therapy.

Anti-human CD38 multi-epitope reagent

Comparative evaluation by flow cytometry of CD38-FITC monoclonal (dark grey dots) and CD38-FITC multi-epitope (CYT-38F2; red dots) performance. A) Bone marrow sample from untreated patient. B) Patient treated with therapy 1. C) Patient treated with therapy 2.


Catalogue code
Multi-epitope-FITC CYT-38F2 50 tests Multi-epitope Multi-epitope CE/IVD pdf-icon

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Cookie Policy.

I accept cookies from this site.

EU Cookie Directive Module Information